The Efficiency And Safety Of Shengbai Oral Solution To Prevent Febrile Neutropenia Induced By Platinum-based Chemotherapy In Lung Cancer

Purpose:The aim of this study was to investigate the efficacy and safety of Shengbai Oral Solution to prevent febrile neutropenia(FN)induced by platinum-based chemotherapy in lung cancer.Patients and Methods:A total of 295 lung cancer patients treated with platinum-based chemotherapy from January 2014 to December 2016 were enrolled in this study.91 patients treated with SBOS were set as treatment group.Using the ratio 1:2 with propensity score match(PS match),168 patients without using Shengbai Oral Solution were matched as control group.The primary end point was the incidence of FN induced by chemotherapy and secondary end points were the incidence of grade 2-4 neutropenia,medical expenses and safety.Results:There were no significant difference between control and treatment group,including gender,age,smoking status,histologic grade,histologic type and chemotherapy program.Compared with control group,Shengbai Oral Solution decreased the incidence of FN induced by platinum-based chemotherapy in the treatment group significantly(2.22% vs 8.88%,p =0.04).Shengbai Oral Solution also decreased the grade 2/3/4,3/4 neutropenia(28.89% vs 55.95%,p<0.001),(13.33% vs 23.81%,HR 0.56,p =0.045).Furthermore,Shengbai Oral Solution did not increase the economic burden on patients and there was no intolerance drug related toxicity.Conclusions:This study revealed that Shengbai Oral Solution was effective and safe on decreasing the incidence of FN and neutropenia induced by platinum-based chemotherapy in lung cancer patients.